Aquinox Pharmaceuticals (AQXP) Releases Quarterly Earnings Results, Beats Estimates By $0.71 EPS

Aquinox Pharmaceuticals (NASDAQ:AQXP) announced its quarterly earnings data on Wednesday. The company reported $0.12 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.59) by $0.71, MarketWatch Earnings reports. The company had revenue of $25.00 million during the quarter.

Aquinox Pharmaceuticals opened at $3.17 on Friday, according to MarketBeat.com. Aquinox Pharmaceuticals has a 12-month low of $1.96 and a 12-month high of $16.90. The company has a market cap of $72.17 million, a price-to-earnings ratio of -1.48 and a beta of -13.81.

Several equities analysts recently commented on the stock. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Aquinox Pharmaceuticals in a research report on Wednesday, June 27th. Guggenheim lowered shares of Aquinox Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $26.00 price target for the company. in a research report on Wednesday, June 27th. Needham & Company LLC lowered shares of Aquinox Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, June 27th. ValuEngine lowered shares of Aquinox Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, June 11th. Finally, Zacks Investment Research raised shares of Aquinox Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a research report on Monday, July 2nd. Five analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Aquinox Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $20.80.

In other Aquinox Pharmaceuticals news, Director Daniel J. Levitt sold 3,906 shares of the firm’s stock in a transaction that occurred on Monday, May 14th. The shares were sold at an average price of $12.67, for a total transaction of $49,489.02. Following the completion of the transaction, the director now directly owns 3,906 shares of the company’s stock, valued at approximately $49,489.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 2.70% of the company’s stock.

About Aquinox Pharmaceuticals

Aquinox Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in developing novel therapeutics for chronic urological conditions by inflammation and pain. The company focuses on a library of novel compounds that activate SH2-containing inositol-5'-phosphatase 1 (SHIP1) to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers.

Read More: Leveraged Buyout (LBO)

Earnings History for Aquinox Pharmaceuticals (NASDAQ:AQXP)

Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply